Evidence map›Paper›PMID 36875106›Full record

ArticleFrontiers in immunology2023

Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.

Entao Li, Qiuxue Han, Jinhao Bi, Shimeng Wei, Shen Wang, Ying Zhang, Jun Liu, Na Feng, Tiecheng Wang, Jun Wu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Entao LiChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Qiuxue HanChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Jinhao BiChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Shimeng WeiChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Shen WangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Ying ZhangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Jun LiuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Na FengChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Tiecheng WangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Jun WuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, China.
Songtao YangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Yongkun ZhaoChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Bo LiuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, China.
Feihu YanChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Xianzhu XiaChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Chinese Academy of Agricultural Sciences · CNJilin Agricultural University · CNNortheast Forestry University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of SARS-CoV-2 variants stresses the continued need for broad-spectrum therapeutic antibodies. Several therapeutic monoclonal antibodies or cocktails have been introduced for clinical use. However, unremitting emerging SARS-CoV-2 variants showed reduced neutralizing efficacy by vaccine induced polyclonal antibodies or therapeutic monoclonal antibodies. In our study, polyclonal antibodies and F(ab')

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, MonoclonalBroadly Neutralizing AntibodiesCricetinaeHorsesHumansImmunoglobulin GMesocricetusMiceMice, Inbred BALB CRodentiaAntibodies, MonoclonalBroadly Neutralizing AntibodiesImmunoglobulin Gbroad-spectrum neutralizing activityequine antibodySARS-CoV-2variants of concernvariants of interest

Identifiers

PMID36875106
PMCPMC9981790
OpenAlexW4321237740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.